QUEBEC CITY, Sept. 16, 2015 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce the hiring of Tony Gibbons as Vice President, Sales and Marketing. He will be responsible for the global commercialization plan for Opsens' products intended to measure Fractional Flow Reserve ("FFR"). Opsens' FFR Products, the OptoWire and OptoMonitor, are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease.
Tony Gibbons spent 20 years with Boston Scientific Corporation in many senior leadership positions including President, Intercontinental and Vice President, International Sales. He was previously Vice President, International at Thoratec Corporation. He holds a Bachelor's degree in Science and majors in Economics and Marketing.
"We are very appreciative to see Tony, a renowned leader of the industry, join us. His expertise in sales and marketing of cardiovascular products will be extremely valuable given the strong growth we anticipate, following the positive reception of the OptoWire in its pre-commercial phase", said Louis Laflamme, President and CEO of Opsens.
"I am very pleased to join Opsens at this defining moment for the Company. The recent receipt of regulatory approval in the United States and the anticipated move into a new state-of-the-art facility will allow Opsens to ramp-up production and grab market shares", said Tony Gibbons.
Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 million in sales in 2014 and is expected to reach US$1 billion in the medium-term.
GRANT OF STOCK OPTIONS
On September 7, 2015, Opsens' Board of Directors approved the grant of 400,000 stock options to Tony Gibbons, pursuant to Opsens' Stock Option Plan adopted by shareholders on January 19, 2015.
The stock options granted will vest over four years at 25 % per year, the first portion vesting at the end of the first year following the granting of the stock options.
Opsens focuses mainly on the measure of Fractional Flow Reserve ("FFR") in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
For further information: Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996; Louis Laflamme, CPA, CA, Chief Executive Officer, 418.682.9996